+

WO2003014960A3 - Anticorps intracellulaires - Google Patents

Anticorps intracellulaires Download PDF

Info

Publication number
WO2003014960A3
WO2003014960A3 PCT/GB2002/003512 GB0203512W WO03014960A3 WO 2003014960 A3 WO2003014960 A3 WO 2003014960A3 GB 0203512 W GB0203512 W GB 0203512W WO 03014960 A3 WO03014960 A3 WO 03014960A3
Authority
WO
WIPO (PCT)
Prior art keywords
identifying
consensus sequence
positions
intracellular antibodies
amino acid
Prior art date
Application number
PCT/GB2002/003512
Other languages
English (en)
Other versions
WO2003014960A2 (fr
Inventor
Antonio Cattaneo
Amos Maritan
Michela Visintin
Terrence Howard Rabbitts
Giovanni Settanni
Original Assignee
Medical Res Council
Sissa Scuola Superiore Interna
Antonio Cattaneo
Amos Maritan
Michela Visintin
Terrence Howard Rabbitts
Giovanni Settanni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0119004A external-priority patent/GB0119004D0/en
Priority claimed from GB0121577A external-priority patent/GB0121577D0/en
Priority claimed from IT2001RM000633A external-priority patent/ITRM20010633A1/it
Priority claimed from GB0200928A external-priority patent/GB0200928D0/en
Priority claimed from GB0203569A external-priority patent/GB0203569D0/en
Priority to CA002456121A priority Critical patent/CA2456121A1/fr
Priority to AU2002355477A priority patent/AU2002355477B2/en
Application filed by Medical Res Council, Sissa Scuola Superiore Interna, Antonio Cattaneo, Amos Maritan, Michela Visintin, Terrence Howard Rabbitts, Giovanni Settanni filed Critical Medical Res Council
Priority to EP02751357A priority patent/EP1425694A2/fr
Priority to JP2003519823A priority patent/JP2004538324A/ja
Publication of WO2003014960A2 publication Critical patent/WO2003014960A2/fr
Priority to US10/771,257 priority patent/US7608453B2/en
Publication of WO2003014960A3 publication Critical patent/WO2003014960A3/fr

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search

Landscapes

  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne une méthode d'identification d'au moins une séquence consensus pour un anticorps intracellulaire consistant à : créer une base de données comprenant des séquences d'anticorps et à aligner lesdites séquences selon Kabat; déterminer la fréquence à laquelle un acide aminé particulier se rencontre dans chacune des positions des anticorps alignés ; sélectionner une valeur de seuil de fréquence (LP ou seuil de consensus) dans la plage 70 %-100 %; identifier les positions d'alignement auxquelles la fréquence d'un acide aminé particulier est supérieure ou égale à la valeur LP; et identifier l'acide aminé le plus fréquemment rencontré dans les positions dedit alignement.
PCT/GB2002/003512 2001-08-03 2002-08-01 Anticorps intracellulaires WO2003014960A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2003519823A JP2004538324A (ja) 2001-08-03 2002-08-01 細胞内抗体
EP02751357A EP1425694A2 (fr) 2001-08-03 2002-08-01 Methode pour identifier la sequence consensus pour des anticorps intracellulaires
CA002456121A CA2456121A1 (fr) 2001-08-03 2002-08-01 Anticorps intracellulaires
AU2002355477A AU2002355477B2 (en) 2001-08-03 2002-08-01 Method of identifying a consensus sequence for intracellular antibodies
US10/771,257 US7608453B2 (en) 2001-08-03 2004-02-03 Intracellular antibodies

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB0119004.0 2001-08-03
GB0119004A GB0119004D0 (en) 2001-08-03 2001-08-03 Antibody
GB0121577A GB0121577D0 (en) 2001-09-06 2001-09-06 Intrabodies
GB0121577.1 2001-09-06
ITRM2001A000633 2001-10-25
IT2001RM000633A ITRM20010633A1 (it) 2001-10-25 2001-10-25 Sequenze consenso per anticorpi intracellulari e loro uso.
GB0200928.0 2002-01-16
GB0200928A GB0200928D0 (en) 2002-01-16 2002-01-16 Intracellular antibodies
GB0203569.9 2002-02-14
GB0203569A GB0203569D0 (en) 2002-02-14 2002-02-14 Intracellular antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/771,257 Continuation-In-Part US7608453B2 (en) 2001-08-03 2004-02-03 Intracellular antibodies

Publications (2)

Publication Number Publication Date
WO2003014960A2 WO2003014960A2 (fr) 2003-02-20
WO2003014960A3 true WO2003014960A3 (fr) 2004-03-11

Family

ID=27516027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/003512 WO2003014960A2 (fr) 2001-08-03 2002-08-01 Anticorps intracellulaires

Country Status (6)

Country Link
US (1) US7608453B2 (fr)
EP (1) EP1425694A2 (fr)
JP (1) JP2004538324A (fr)
AU (1) AU2002355477B2 (fr)
CA (1) CA2456121A1 (fr)
WO (1) WO2003014960A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49435E1 (en) 2014-11-12 2023-02-28 Seagen Inc. Glycan-interacting compounds and methods of use

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003077945A1 (fr) * 2002-03-14 2003-09-25 Medical Research Council Anticorps intracellulaires
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
GB0226723D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Antibodies for in vitro use
EP2368997A3 (fr) 2005-03-25 2012-02-22 National Research Council of Canada Procédé d'isolation de polypeptides solubles
EP1888640B1 (fr) 2005-05-18 2012-03-14 Ablynx N.V. Nanocorps ameliores utilises contre le facteur-alpha de necrose tumorale
PL2444424T3 (pl) 2005-05-20 2019-01-31 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
PL2481756T3 (pl) 2005-10-31 2018-02-28 Oncomed Pharmaceuticals, Inc. Kompozycje i sposoby diagnozowania i leczenia nowotworu
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5247009B2 (ja) * 2006-06-16 2013-07-24 独立行政法人理化学研究所 配列抽出装置、配列抽出方法、プログラムおよび記録媒体
CA2672965C (fr) 2006-12-19 2018-02-06 Ablynx N.V. Sequences d'acides amines dirigees contre une metalloproteinase de la famille adam et polypeptides les comprenant a des fins de traitement de maladies et troubles lies a adam
EP2115004A2 (fr) 2006-12-19 2009-11-11 Ablynx N.V. Sequences d'acides amines dirigees contre les gpcr et polypeptides les contenant pour le traitement de maladies et de troubles lies au gpcr
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2947097A1 (fr) 2008-04-07 2015-11-25 Ablynx N.V. Séquences d'acides aminés dirigées contre les voies Notch et leurs utilisations
CN105079805A (zh) 2008-09-26 2015-11-25 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
RU2016103067A (ru) 2009-06-05 2018-11-20 Аблинкс Нв Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей
GB0911215D0 (en) 2009-06-29 2009-08-12 Univ Erasmus Medical Ct Gamma globin therapy
WO2011064382A1 (fr) 2009-11-30 2011-06-03 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre le virus syncytial respiratoire humain (hrsv) et polypeptides comprenant celles-ci pour la prévention et/ou le traitement d'infections du tractus respiratoire
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2011083140A1 (fr) 2010-01-08 2011-07-14 Ablynx Nv Domaines variables simples d'immunoglobuline dirigés contre le cxcr4 doués d'une meilleure activité thérapeutique et produits de recombinaison les comprenant
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011123785A2 (fr) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Agents de liaison aux récepteurs frizzled et leurs utilisations
PH12012502272A1 (en) 2010-05-20 2017-07-26 Ablynx Nv Biological materials related to her3
EA031698B1 (ru) 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Человеческие анти-тау антитела
UA115027C2 (uk) 2010-11-08 2017-09-11 Новартіс Аг Cxcr2-зв'язуючі поліпептиди
CA2827170A1 (fr) 2011-02-11 2012-08-16 David M. Hilbert Complexes plurispecifiques monovalents et multivalents et leurs utilisations
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EA032929B1 (ru) * 2011-05-17 2019-08-30 Дзе Рокфеллер Юниверсити Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
WO2012175740A1 (fr) 2011-06-23 2012-12-27 Ablynx Nv Domaines variables uniques d'immunoglobuline dirigés contre ige
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP2674439B1 (fr) 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anticorps anti-TrkA, dérivés et utilisations associés
PE20150646A1 (es) 2012-08-16 2015-05-21 Ipierian Inc Metodos de tratamiento de una tauopatia
PT2888283T (pt) 2012-08-24 2018-11-16 Univ California Anticorpos e vacinas para serem utilizados no tratamento de cancros que expressam ror1 e inibição de metástases
WO2014066328A1 (fr) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Méthodes de traitement de tumeurs neuro-endocrines à l'aide d'agents liants de parcours wnt
WO2014087010A1 (fr) 2012-12-07 2014-06-12 Ablynx N.V. Polypeptides améliorés dirigés contre ige
AU2013361107B2 (en) 2012-12-21 2018-08-23 Biogen International Neuroscience Gmbh Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2014182676A2 (fr) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions et procédés de modulation du facteur de croissance
EP3104870A4 (fr) 2014-02-14 2017-09-13 Ipierian, Inc. Peptides tau, anticorps anti-tau, et leurs procédés d'utilisation
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
LT3294319T (lt) 2015-05-13 2024-08-12 Ablynx Nv T ląsteles sutelkiantys polipeptidai pagal cd3 reaktyvumą
ES2754427T3 (es) 2015-05-13 2020-04-17 Ablynx Nv Polipéptidos de reclutamiento de células T basados en la reactividad de TCR alfa/beta
ITUB20155272A1 (it) 2015-11-02 2017-05-02 Scuola Normale Superiore Intracellular antibody
CA3002097A1 (fr) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Composes interagissant avec le glycane et methodes d'utilisation
KR20240113990A (ko) 2016-06-27 2024-07-23 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
EP3509622A4 (fr) 2016-09-08 2020-06-17 Regenerative Research Foundation Polypeptides anti-tau bi-fonctionnels et leur utilisation
CA3034643A1 (fr) 2016-09-20 2018-03-29 Ellen Weisberg Compositions et methodes pour l'identification, l'evaluation, la prevention et le traitement de la lma au moyen de biomarqueurs usp10 et de modulateurs
KR102665596B1 (ko) 2016-11-16 2024-05-14 아블린쓰 엔.브이. Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
EP3589319A4 (fr) 2017-03-03 2021-07-14 Seagen Inc. Composés interagissant avec le glycane et méthodes d'utilisation
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
CN111032873A (zh) 2017-06-26 2020-04-17 国立研究开发法人理化学研究所 融合蛋白
US20210032334A1 (en) 2018-02-28 2021-02-04 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
EP3962529A4 (fr) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. Méthodes de traitement du cancer à l'aide de combinaisons d'agents anti-cx3cr1 et d'agents de blocage de points de contrôle immunitaires
WO2020245663A1 (fr) 2019-06-01 2020-12-10 Institut Pasteur Dosage ns1 à base de nanocorps pour le diagnostic spécifique d'une infection aiguë par le virus zika
EP3767628B1 (fr) * 2019-07-18 2024-03-27 Bayer Aktiengesellschaft Sélection d'anticorps / de fragments d'anticorps
US20230075965A1 (en) 2020-01-24 2023-03-09 Constantine S. Mitsiades Uses of biomarkers for improving immunotherapy
US20240158864A1 (en) 2021-01-25 2024-05-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
US20250009743A1 (en) 2021-02-11 2025-01-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancers using sting agonists
AU2022224636A1 (en) 2021-02-19 2023-09-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that neutralize sars-cov-2
EP4301777A1 (fr) 2021-03-02 2024-01-10 Dana-Farber Cancer Institute, Inc. Procédés de traitement de troubles des globules rouges
EP4319800A1 (fr) 2021-04-07 2024-02-14 Dana-Farber Cancer Institute, Inc. Compositions et procédés pour le traitement du cancer
US20240280561A1 (en) 2021-06-08 2024-08-22 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
US20250011767A1 (en) 2021-11-18 2025-01-09 Circularis Biotechnologies, Inc. Compositions and methods for production of circular nucleic acid molecules
EP4440594A2 (fr) 2021-11-29 2024-10-09 Dana-Farber Cancer Institute, Inc. Méthodes et compositions pour moduler riok2
AU2023313033A1 (en) 2022-07-27 2025-03-13 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024083843A1 (fr) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Séquences d'acides aminés dirigées contre le récepteur de la mélanocortine 4 et polypeptides les comprenant pour le traitement de maladies et de troubles liés à mc4r
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
US20250129145A1 (en) 2023-09-22 2025-04-24 Ablynx N.V. Bi- and multivalent albumin binders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008320A1 (fr) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Banques de proteines/(poly)peptides
US5681722A (en) * 1991-07-25 1997-10-28 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
WO1999015897A1 (fr) * 1997-09-19 1999-04-01 Chiron Corporation Procede de criblage soustractif de proteines servant a identifier des genes
GB2344886A (en) * 1999-03-10 2000-06-21 Medical Res Council Selection of intracellular immunoglobulins
WO2002002641A1 (fr) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU2003224916B2 (en) * 2002-04-10 2009-01-08 Genentech, Inc. Anti-HER2 antibody variants

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681722A (en) * 1991-07-25 1997-10-28 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
WO1997008320A1 (fr) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Banques de proteines/(poly)peptides
WO1999015897A1 (fr) * 1997-09-19 1999-04-01 Chiron Corporation Procede de criblage soustractif de proteines servant a identifier des genes
GB2344886A (en) * 1999-03-10 2000-06-21 Medical Res Council Selection of intracellular immunoglobulins
WO2002002641A1 (fr) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 1 May 2000 (2000-05-01), Database accession no. Q9UL90 *
DATABASE EMBL [online] 10 January 2002 (2002-01-10), Database accession no. ABP45690 *
DATABASE EMBL [online] 21 July 1986 (1986-07-21), Database accession no. P01763 *
DATABASE EMBL [online] 22 January 1998 (1998-01-22), Database accession no. AAW27546 *
DATABASE EMBL [online] 3 April 1998 (1998-04-03), Database accession no. I71718 *
GONI F ET AL: "AMINO-ACID SEQUENCE OF THE FV REGION OF A HUMAN MONO CLONAL IMMUNO GLOBULIN M PROTEIN WEA WITH ANTIBODY ACTIVITY AGAINST 3 4 PYRUVYLATED GALACTOSE IN KLEBSIELLA POLY SACCHARIDES K-30 AND K-33", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 80, no. 15, P01763, 1983, 1983, pages 4837 - 4841, XP009022812, ISSN: 0027-8424 *
OHAGE ETTORE C ET AL: "Intrabody construction and expression. II. A synthetic catalytic Fv fragment.", JOURNAL OF MOLECULAR BIOLOGY, vol. 291, no. 5, pages 1129 - 1134, XP002255005, ISSN: 0022-2836 *
OHAGE ETTORE ET AL: "Intrabody construction and expression. I. The critical role of VL domain stability", JOURNAL OF MOLECULAR BIOLOGY, vol. 291, no. 5, 3 September 1999 (1999-09-03), pages 1119 - 1128, XP002264538, ISSN: 0022-2836 *
PROBA KARL ET AL: "Antibody scFv fragments without disulfide bonds made by molecular evolution.", JOURNAL OF MOLECULAR BIOLOGY, vol. 275, no. 2, 16 January 1998 (1998-01-16), pages 245 - 253, XP002255006, ISSN: 0022-2836 *
VISINTIN MICHELA ET AL: "The intracellular antibody capture technology (IACT): Towards a consensus sequence for intracellular antibodies.", JOURNAL OF MOLECULAR BIOLOGY, vol. 317, no. 1, 2002, 15 March, 2002, pages 73 - 83, XP002255025, ISSN: 0022-2836 *
WIRTZ PETER ET AL: "Intrabody construction and expression III: Engineering hyperstable VH domains.", PROTEIN SCIENCE, vol. 8, no. 11, November 1999 (1999-11-01), pages 2245 - 2250, XP009017215, ISSN: 0961-8368 *
WU XIAOBING ET AL: "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 87, no. 2, May 1998 (1998-05-01), pages 184 - 192, XP002264539, ISSN: 0090-1229 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49435E1 (en) 2014-11-12 2023-02-28 Seagen Inc. Glycan-interacting compounds and methods of use

Also Published As

Publication number Publication date
US7608453B2 (en) 2009-10-27
EP1425694A2 (fr) 2004-06-09
CA2456121A1 (fr) 2003-02-20
AU2002355477B2 (en) 2008-09-25
WO2003014960A2 (fr) 2003-02-20
JP2004538324A (ja) 2004-12-24
US20050288864A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
WO2003014960A3 (fr) Anticorps intracellulaires
WO2004056865A3 (fr) Methode de modulation de l'interaction d'un recepteur et d'un ligand
DE60322188D1 (de) Zytokin (zcytor17-ligand)
WO2001059066A3 (fr) Conception automatisee de proteine destinee a des bibliotheques de proteines
DE69938054D1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
WO2002042427A3 (fr) Marqueurs de masse pour analyse quantitative
WO2003048302A3 (fr) Identification de cibles ou d'agents antitumoraux par immunisation et proteomique des radeaux lipidiques
WO2000023564A3 (fr) Automatisation de la conception des proteines pour l'elaboration des bibliotheques de proteines
WO2002095356A3 (fr) Procedes et compositions pour l'analyse de proteines
FI3718564T3 (fi) Uusia anti-IL 13 -vasta-aineita ja niiden käyttöjä
WO2002072605A3 (fr) Technique d'expression pour des proteines contenant un fragment d'anticorps isotype chimerique
BRPI0409269A (pt) anticorpo modificado da classe igg e método de produção do mesmo
WO2004022717A3 (fr) Variants tres faiblement immunogenes de l'anticorps humanise col-1 contre l'antigene carcino-embryonnaire
AU2002239882A1 (en) Method for identifying a ligand for a biological substrate
WO1996040766A3 (fr) Domaines de liaison issus des proteines de liaison erythrocytaire derivees de plasmodium vivax et de plasmodium falciparum
WO2005062947A3 (fr) Methodes et compositions d'identification de proteines de liaison a l'arn
WO2004046314A3 (fr) Procedes de detection de dimethylarginine asymetrique dans un echantillon biologique
WO2006094185A3 (fr) Quantification de proteines
WO2003016904A3 (fr) Etiquettes de sequence peptidique et leur procede d'utilisation
WO2004039842A3 (fr) Anticorps humanises anti-facteur tissulaire
WO2005005632A3 (fr) PETITS ARN INTERFERENTS SPECIFIQUES DES SOUS-UNITES α, α' ET β DE LA PROTEINE KINASE CK2 ET LEURS APPLICATIONS
EP1182253A3 (fr) Procédé pour l' amélioration de la stabilité thermique de protéines
WO2002090989A3 (fr) Procede permettant de detecter des antigenes de globules sanguins et des anticorps diriges contre ces antigenes
CA2441187A1 (fr) Anticorps monoclonal reconnaissant l'acetyllysine et son procede de production
WO2003073351A3 (fr) Procede de criblage

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002355477

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2456121

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003519823

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002751357

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002751357

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载